All In Biotech

Drug Trial Radar · NCT07444424

A Study to Investigate the Effect of AZD5004 on Mitiglinide and Pioglitazone in Healthy Participants

An Open-label, Fixed-sequence, Two-part Study to Assess the Effect of AZD5004 on the Pharmacokinetics of Mitiglinide and Pioglitazone in Healthy Participants

Last checked: Nov 19, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

32

Actual

Start

Mar 13, 2026

Primary completion

Jul 2, 2026

Study completion Jul 2, 2026

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Parexel
First posted
Mar 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of the study is to assess the effect of AZD5004 on the pharmacokinetics (PK) of mitiglinide and pioglitazone in healthy participants.

Conditions

  • Healthy Participants

Interventions

  • AZD5004Drug

    AZD5004 will be administered orally.

  • MitiglinideDrug

    Mitiglinide will be administered orally.

  • PioglitazoneDrug

    Pioglitazone will be administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under concentration-time curve from time 0 to infinity (AUCinf)Time frame: Part A: From Day 1 to Day 50; Part B: From Day 1 to Day 70
  2. Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast)Time frame: Part A: From Day 1 to Day 50; Part B: From Day 1 to Day 70
  3. Maximum observed drug concentration (Cmax)Time frame: Part A: From Day 1 to Day 50; Part B: From Day 1 to Day 70

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Fukuoka, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.